Dental Care Clinics in Ketchikan, AK Accepting Medicare
7 Dental Care Clinics found. Showing 1 - 7
 Linsenmayer Dentistry, Llc Dentist Medicare: Not Enrolled in Medicare Practice Location: 21 Jefferson Way Ste 102, Ketchikan, AK 99901 Phone: 907-220-9231 |
Jason W. Evison, D.d.s., P.c. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1621 Tongass Ave, Suite 103, Ketchikan, AK 99901 Phone: 907-225-8228 |
Kic Tribal Health Clinic Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 2960 Tongass Ave, Ketchikan, AK 99901 Phone: 907-228-9200 Fax: 800-887-8796 |
Ketchikan Dental Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 130 Carlanna Lake Rd, Ketchikan, AK 99901 Phone: 909-967-8052 Fax: 907-331-4220 |
Peter Emmons Dentist Medicare: Not Enrolled in Medicare Practice Location: 130 Carlanna Lake Rd, Ketchikan, AK 99901 Phone: 832-726-6655 |
David A Albertson Dds Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 130 Carlanna Lake Rd, Ketchikan, AK 99901 Phone: 907-225-9631 |
Thomas B. Nordtvedt, Dds, Apc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1621 Tongass Ave, Suite 103, Ketchikan, AK 99901 Phone: 907-225-8228 Fax: 907-225-8224 |
News Archive
Air pollution raises risk of stroke and cognitive decline
According to data from two studies published in the Archives of Internal Medicine exposure to air pollution may have serious cognitive and cardiovascular health consequences, even at levels currently deemed acceptable by the U.S. Environmental Protection Agency (EPA).
Researchers shed light on involvement of immune system in schizophrenia
Using data from the largest ever genetic study of schizophrenia, researchers have shed light on the role of the immune system.
Bio-Reference Laboratories reports third-quarter fiscal 2009 revenues
Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) (Except for Per Share Data or where otherwise noted, numbers are in thousands) announced that the Company recorded current quarter revenues of $97,424, the best ever quarter in terms of revenues in corporate history and an increase of more than 25% over the $77,776 recorded in the third quarter, fiscal year 2008.
Kamada reports positive data with inhaled Alpha-1 Antitrypsin in cystic fibrosis
Kamada has announced today positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin (AAT) delivered via an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in the treatment of cystic fibrosis. The results demonstrate the product has an excellent safety profile and shows promising signs of efficacy, as indicated by a reduction in lung inflammation.
KAUST-led researchers reveal epigenetic mechanism for gene regulation
An epigenetic mechanism regulating gene activity has been revealed by a KAUST-led international team of researchers investigating interactions between the human genome and its environment in adult tissues.
› Verified 9 days ago